In a randomized clinical trial which involved 1532 men who were diagnosed with prostate cancer and went on to receive primary radiation treatment it was found that dose escalated radiotherapy provided a significant improvement in clinical endpoints like biochemical failure (PSA only recurrence), and the development of distant metastases. However, dose escalated radiation therapy did not improve their overall survival!
The men who did receive dose escalated radio therapy had less need for secondary therapies, but they did not have any survival advantage.
JAMA Oncol 2018 Mar 15;[EPub Ahead of Print], JM Michalski, J Moughan, J Purdy, W Bosch, DW Bruner, JP Bahary, H Lau, M Duclos, M Parliament, G Morton, D Hamstra, MSeider, MI Lock, M Patel, H Gay, E Vigneault, K Winter, H Sandler
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.
